We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 09, 2021

Azacitidine vs a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated AML

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
A Phase 3 Trial of Azacitidine Versus a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated Acute Myeloid Leukemia
Cancer 2021 Feb 24;[EPub Ahead of Print], S Vives, D Martínez-Cuadrón, J Bergua Burgues, L Algarra, M Tormo, MP Martínez-Sánchez, J Serrano, P Herrera, F Ramos, O Salamero, E Lavilla, JL López-Lorenzo, C Gil, B Vidriales, JF Falantes, A Serrano, J Labrador, MJ Sayas, MÁ Foncillas, ML Amador Barciela, MT Olave, M Colorado, A Gascón, MÁ Fernández, A Simiele, MM Pérez-Encinas, R Rodríguez-Veiga, O García, J Martínez-López, E Barragán, B Paiva, MÁ Sanz, P Montesinos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading